Clinical Trial Update: Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of cytarabine (Ara-C) and aclarubicin with pegylated G-CSF (PEG-G-CSF) as initial treatment for acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aclarubicin (aclarubicin)
• Cytarabine (Ara-C) (cytarabine)
• Pegylated G-CSF (PEG-G-CSF) (pegylated granulocyte colony-stimulating factor)

Snippet

Sponsor: Shandong University | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN